Table 3 Patient characteristics and expression of pS 21 GSK3α, pS 9 GSK3β, cyclin D1 and P53 in oral cancer and control tissue samples
Sl. No. | Groups | Total (n = 39) | Samples showing the positive expression of proteins (n) | |||
|---|---|---|---|---|---|---|
Cyclin D1 | P53 | pS 21 GSK3α | pS 9 GSK3β | |||
1 | Age | |||||
≤40 | 23 | 17 (73.9%) | 08 (34.7%) | 12 (52.1%) | 14 (60.8%) | |
>40 ≤ 70 | 16 | 08 (50.0%) | 08 (50.0%) | 10 (62.5%) | 09 (56.2%) | |
2 | Sex | |||||
Male | 23 | 14 (60.8%) | 10 (43.4%) | 13 (56.5%) | 14 (60.8%) | |
Female | 16 | 11 (68.7%) | 06 (37.5%) | 09 (56.2%) | 09 (56.2%) | |
3 | Histological grade/Tumour Progression | |||||
Normal | 6 | 00 (00.0%) | 01 (16.6%) | 00 (00.0%) | 00 (00.0%) | |
PML | 6 | 06 (100%) | 03 (50.0%) | 01 (16.6%) | 02 (33.3%) | |
WDSCC | 15 | 10 (66.6%) | 07 (46.6%) | 10 (66.6%) | 11 (73.3%) | |
MDSCC | 6 | 06 (100%) | 05 (83.3%) | 06 (100%) | 05 (83.3%) | |
PDSCC | 6 | 03 (50.0%) | 01 (16.6%) | 05 (83.3%) | 05 (83.3%) | |
4 | Tobacco History | |||||
Yes | 23s | 14 (60.8%) | 11 (47.8%) | 12 (52.1%) | 13 (56.5%) | |
No | 16 | 11 (68.7%) | 05 (31.2%) | 10 (62.5%) | 10 (62.5%) | |
5 | pS 21 GSK3α Expression | |||||
Positive | 22 | 18 (81.8%) | 12 (54.5%) | 22 (100%) | 20 (90.9%) | |
Not-Positive | 17 | 07 (41.1%) | 04 (23.5%) | 00 (00.0%) | 03 (17.6%) | |
6 | pS 9 GSK3β Expression | |||||
Positive | 23 | 18 (78.2%) | 11 (47.8%) | 20 (86.9%) | 23 (100%) | |
Not Positive | 16 | 07 (43.7%) | 05 (31.2%) | 02 (12.5%) | 00 (00.0%) | |